Wave Life Sciences
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average and near the bottom of the universe on momentum.
- Signal has read STRONG SELL for 4 months.
- Its last 11 Sell calls were actually followed by a +29% average gain three months out - this one has bounced back faster than the signal expected.
- Recent price momentum is -56.7% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has risen to 10.5% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2849 U.S. stocks StockVane covers.
Last computed: 2026-11-21 14:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability F
How much profit the business keeps from each dollar of sales and capital.
| Operating margin | -504.1% | Better than 4% |
| Net margin | -478.3% | Better than 4% |
| Return on equity | -56.2% | Better than 8% |
| Return on invested capital | -53.0% | Better than 5% |
Momentum F
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -51.6% | Better than 5% |
| 6-month return | -59.9% | Better than 4% |
| 12-month return (ex latest month) | -52.5% | Better than 2% |
| Distance below 52-week high | 88.2% | Better than 1% |
Financial Health B+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 6.5x | Better than 90% |
| Debt to assets | 2.8% | Better than 85% |
| Interest coverage | -427.8x | Better than 3% |
Analyst View A+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 92.9% | Better than 75% |
| Upside to average target | 457.8% | Better than 99% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 2.72
- Open
- 2.65
- Day range
- 2.55 - 2.79
- Avg price
- 2.62
- Volume
- 2.28M
- Turnover
- 5.98M
- Turnover ratei
- 2.18%
- Volume ratioi
- 0.96
- Amplitudei
- 9.01%
- 52-week rangei
- 2.55 - 21.73
Valuation
- P/Ei
- -2.12
- P/E (TTM)i
- -2.39
- P/Bi
- 1.26
- EPSi
- -1.21
- Book value / shi
- 2.04
- Net profit
- -238.65M
- Net assets
- 401.95M
Share structure
- Market cap
- 504.91M
- Float capi
- 268.77M
- Shares out
- 197.23M
- Float sharesi
- 104.99M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2015-11-11
88.2% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+5.89M net over the window
Short interest
- Shares short
- 20.65M
- % of floati
- 10.47%
- Days to coveri
- 6.76
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Wave Life Sciences (WVE)?
Wave Life Sciences last traded at 2.56. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Wave Life Sciences's market cap?
About 504.91M.
What is the P/E ratio of Wave Life Sciences?
The trailing twelve-month P/E is -2.39. The Valuation tab shows it against the stock's own five-year range.
Does Wave Life Sciences pay a dividend?
Wave Life Sciences does not currently pay a regular dividend.
Is Wave Life Sciences a buy according to analysts?
The consensus of 14 analysts is a Buy rating, with an average 12-month price target of 14.28, which implies 457.8% upside from the current price. This is not investment advice.
What is Wave Life Sciences's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Wave Life Sciences a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.
Quote time 2026-11-20 19:33:51 · For reference only, not investment advice and not tailored to your situation.
Wave Life Sciences discussion 0 comments